
GOSS Stock Forecast & Price Target
GOSS Analyst Ratings
Bulls say
Gossamer Bio Inc. has garnered unusually bullish sentiment from key opinion leaders (KOLs), particularly regarding the expected success of its PAH treatment, PROSERA, with anticipated treatment effects ranging between 25m to 30m in the 6MWD metric. Despite some limitations in the phase 2 TORREY data, consistent benefits have been demonstrated across multiple endpoints, underscoring the product's potential with clean safety profiles and promising durability in long-term outcomes. The company has also seen increased investor interest following positive commentary at recent conferences, signaling strong market confidence in their pipeline and future growth potential.
Bears say
Gossamer Bio Inc. is facing a negative outlook primarily due to persistent mispricing in the market concerning the probability of success for its pipeline product, Seralutinib. Despite a recent increase in stock value, the underlying assumptions regarding Seralutinib's odds do not align with its clinical prospects, suggesting overvaluation. This disconnect raises concerns about the long-term viability of Gossamer Bio's financial foundation, particularly as it relates to its advancement in the competitive biopharmaceutical sector.
This aggregate rating is based on analysts' research of Gossamer Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
GOSS Analyst Forecast & Price Prediction
Start investing in GOSS
Order type
Buy in
Order amount
Est. shares
0 shares